Eikon Therapeutics, Inc. Common Stock (EIKN) — Cash Flow-to-Debt Ratio
Eikon Therapeutics, Inc. Common Stock (EIKN) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of $-41.72 Million could theoretically repay 0% of its total liabilities ($1.47 Billion) in one year. See working capital position of Eikon Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eikon Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for Eikon Therapeutics, Inc. Common Stock across 3 annual periods. Also explore net asset growth rate of Eikon Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eikon Therapeutics, Inc. Common Stock (2023–2025)
Year-by-year debt coverage analysis for Eikon Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see EIKN company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | $-188.52 Million | $1.47 Billion | ▼ -0.9% |
| 2024 | -0.13x | $-134.80 Million | $1.06 Billion | ▲ +42.4% |
| 2023 | -0.22x | $-190.85 Million | $867.08 Million | — |